These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34353608)

  • 1. 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties.
    Nilewski C; Michels TD; Packard GK; Xiang AX; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Ernst JT; Reich SH
    Bioorg Med Chem Lett; 2021 Sep; 47():128111. PubMed ID: 34353608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A Inhibitors.
    Nilewski C; Michels TD; Xiang AX; Packard GK; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Ernst JT; Reich SH
    Org Lett; 2020 Aug; 22(16):6257-6261. PubMed ID: 32806219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
    Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
    Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
    Ernst JT; Thompson PA; Nilewski C; Sprengeler PA; Sperry S; Packard G; Michels T; Xiang A; Tran C; Wegerski CJ; Eam B; Young NP; Fish S; Chen J; Howard H; Staunton J; Molter J; Clarine J; Nevarez A; Chiang GG; Appleman JR; Webster KR; Reich SH
    J Med Chem; 2020 Jun; 63(11):5879-5955. PubMed ID: 32470302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A.
    Basmadjian C; Thuaud F; Ribeiro N; Désaubry L
    Future Med Chem; 2013 Dec; 5(18):2185-97. PubMed ID: 24261894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
    Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
    Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified silvestrol analogues with potent cytotoxic activity.
    Hawkins BC; Lindqvist LM; Nhu D; Sharp PP; Segal D; Powell AK; Campbell M; Ryan E; Chambers JM; White JM; Rizzacasa MA; Lessene G; Huang DC; Burns CJ
    ChemMedChem; 2014 Jul; 9(7):1556-66. PubMed ID: 24677741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
    Rodrigo CM; Cencic R; Roche SP; Pelletier J; Porco JA
    J Med Chem; 2012 Jan; 55(1):558-62. PubMed ID: 22128783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
    Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
    Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.
    Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
    Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.
    Tillotson J; Kedzior M; Guimarães L; Ross AB; Peters TL; Ambrose AJ; Schmidlin CJ; Zhang DD; Costa-Lotufo LV; Rodríguez AD; Schatz JH; Chapman E
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4082-4085. PubMed ID: 28757063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
    Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
    Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.
    Bordeleau ME; Robert F; Gerard B; Lindqvist L; Chen SM; Wendel HG; Brem B; Greger H; Lowe SW; Porco JA; Pelletier J
    J Clin Invest; 2008 Jul; 118(7):2651-60. PubMed ID: 18551192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds.
    Schulz G; Victoria C; Kirschning A; Steinmann E
    Nat Prod Rep; 2021 Jan; 38(1):18-23. PubMed ID: 32699874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.
    Chu J; Galicia-Vázquez G; Cencic R; Mills JR; Katigbak A; Porco JA; Pelletier J
    Cell Rep; 2016 Jun; 15(11):2340-7. PubMed ID: 27239032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol.
    Cencic R; Carrier M; Galicia-Vázquez G; Bordeleau ME; Sukarieh R; Bourdeau A; Brem B; Teodoro JG; Greger H; Tremblay ML; Porco JA; Pelletier J
    PLoS One; 2009; 4(4):e5223. PubMed ID: 19401772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
    Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
    Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas.
    Oblinger JL; Wang J; Wetherell GD; Agarwal G; Wilson TA; Benson NR; Fenger JM; Fuchs JR; Kinghorn AD; Chang LS
    Sci Rep; 2024 Aug; 14(1):19349. PubMed ID: 39164287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.
    Iwasaki S; Iwasaki W; Takahashi M; Sakamoto A; Watanabe C; Shichino Y; Floor SN; Fujiwara K; Mito M; Dodo K; Sodeoka M; Imataka H; Honma T; Fukuzawa K; Ito T; Ingolia NT
    Mol Cell; 2019 Feb; 73(4):738-748.e9. PubMed ID: 30595437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel flavaglines displaying improved cytotoxicity.
    Thuaud F; Ribeiro N; Gaiddon C; Cresteil T; Désaubry L
    J Med Chem; 2011 Jan; 54(1):411-5. PubMed ID: 21142180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.